While skeletal muscle is the biggest component of LBM, it is not the only one, and changes in LBM do not translate directly to changes in muscle
Shi K, et al
Understanding your options and what to expect Delivery timing and how the process works General questions before you decide Who Is Eligible for a GLP-1 Plan in the UK
doi: References Kieffer, T
b , Overlay of TT-OAD2-bound GLP-1R G s structure with the full-length peptide bound G s structures and the inactive glucagon receptor (GCGR

Current UK professional guidance emphasises: Patients should inform their surgical team and anaesthetist that they are taking a GLP-1 medication as soon as surgery is planned Healthcare professionals should specifically ask about GLP-1 use during preoperative assessment, as patients may not recognise these medications as relevant to their surgery The decision to continue or pause GLP-1 therapy should be made on an individual risk-based assessment , considering the type of surgery, the specific GLP-1 agent, dose escalation status, presence of gastrointestinal symptoms, and the patient's clinical circumstances Many patients can safely continue GLP-1 medications perioperatively with appropriate precautions, while those at higher risk may benefit from temporary cessation The Summary of Product Characteristics (SmPC) for GLP-1 medications notes the delayed gastric emptying effect, which anaesthetists consider when planning perioperative care